FSCDR Presents Positive Results from Case Study of Voxelotor (GBT440) in Sickle Cell Disease Patient

HOLLYWOOD, Fla., — Oct. 31, 2017 — On Oct. 28, Lanetta Bronté, M.D., M.P.H., M.S.P.H. presented a positive results case study for a sickle cell patient with severe and symptomatic anemia, after receiving voxelotor, at the 45th Annual National Convention hosted by the Sickle Cell Disease Association of America in Atlanta. Dr Bronté, president…

Read More

FSCDR’s Experience with Voxelotor (GBT440) Treatment in Patients with Severe Sickle Cell Disease

ATLANTA — Lanetta Bronté, M.D., M.P.H., M.S.P.H., founder and chief health officer of the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Fla., presented results from seven adult sickle cell disease patients with severe anemia and multiple co-morbidities who were not eligible to participate in Global Blood Therapeutics’s (GBT) Phase 3 HOPE (Hemoglobin…

Read More